today
global
economi
afford
vacat
travel
increasingli
import
visitor
anoth
countri
physician
familiar
emerg
infect
infect
uniqu
specif
geograph
region
risk
relat
process
travel
never
import
patient
primari
immunodefici
disord
pidd
recent
review
address
common
caus
fever
travel
provid
import
inform
gener
popul
review
cover
critic
infecti
manag
concern
specif
relat
travel
patient
pidd
review
discuss
context
chang
landscap
infect
highlight
specif
infect
concern
profil
distinct
infect
phenotyp
patient
immun
compromis
organ
review
address
environ
drive
emerg
infect
sever
concern
uniqu
patient
pidd
first
section
address
gener
consider
second
section
profil
specif
infect
organ
accord
mechan
transmiss
third
section
focus
uniqu
phenotyp
uniqu
suscept
patient
pidd
review
address
parasit
diseas
refer
tabl
provid
easili
access
inform
broader
rang
infect
describ
text
physician
familiar
emerg
infect
infect
uniqu
specif
geograph
region
risk
relat
process
travel
never
import
patient
primari
immunodefici
disord
pidd
recent
review
address
common
caus
fever
travel
provid
import
inform
gener
popul
review
cover
critic
infecti
manag
concern
specif
relat
travel
patient
pidd
review
discuss
context
chang
landscap
infect
highlight
specif
infect
concern
profil
distinct
infect
phenotyp
patient
immun
compromis
organ
review
address
environ
drive
emerg
infect
sever
concern
uniqu
patient
pidd
first
section
address
gener
consider
second
section
profil
specif
infect
organ
accord
mechan
transmiss
third
section
focus
uniqu
phenotyp
uniqu
suscept
patient
pidd
review
address
parasit
diseas
refer
tabl
provid
easili
access
inform
broader
rang
infect
describ
text
emerg
infecti
diseas
result
converg
numer
factor
compris
complex
interact
among
multipl
variabl
factor
human
movement
land
use
chang
encroach
wildlif
transloc
rapid
transport
climat
chang
sever
studi
demonstr
pathogen
persist
popul
minim
host
popul
size
specif
type
pathogen
host
popul
particular
relev
emerg
infect
pattern
rapid
popul
growth
tropic
wwii
region
ecosystem
consist
larg
citi
scatter
human
settlement
separ
larg
area
cropland
pastureland
undisturb
forest
today
pattern
opposit
mani
larg
citi
develop
patch
undisturb
forest
grassland
domest
vector
therefor
expand
popul
increas
urban
markedli
impact
interact
vector
pathogen
human
activ
deforest
use
pesticid
pollut
etc
lead
loss
predat
natur
regul
rodent
insect
popul
contribut
emerg
zoonot
diseas
explain
occur
frequent
area
recent
settl
today
global
economi
afford
vacat
travel
increasingli
import
visitor
anoth
countri
southern
reduct
number
cold
day
per
year
chang
rainfal
winter
precipit
summer
drought
togeth
chang
increas
risk
sever
vectorborn
diseas
new
area
climat
chang
involv
global
warm
also
chang
precipit
wind
humid
locat
frequenc
extrem
weather
event
like
flood
drought
heat
wave
chang
climat
produc
chang
pathogen
vector
host
live
environ
increas
precipit
increas
mosquito
exampl
heavi
rainfal
may
caus
flood
temporarili
elimin
larval
habitat
decreas
mosquito
flood
may
forc
rodent
look
new
habitat
hous
increas
opportun
vectorhuman
interact
occur
exampl
case
epidem
leptospirosi
humid
anoth
import
factor
climat
chang
develop
vectorborn
diseas
mosquito
tick
surviv
well
dri
condit
therefor
weather
impact
infecti
pathogen
distribut
complex
way
predict
forecast
extrem
weather
event
precipit
outbreak
infect
increas
frequenc
intens
natur
disast
like
hurrican
tsunami
relat
el
oscil
phenomenon
may
result
flood
grassland
favor
breed
aed
culex
mosquito
impact
water
sanit
foster
outbreak
cholera
flood
area
displac
rodent
lead
plagu
tornado
sever
weather
stir
soil
lead
infect
soil
fungi
lead
episod
outbreak
invas
fungal
diseas
mucormycosi
apophysomyc
trapeziformi
malaria
common
diseas
vari
dramat
depend
weather
extrem
weather
alter
landscap
provid
new
bodi
water
support
larval
develop
melt
glacier
polar
ice
cap
bring
coastal
citi
underwat
overpopul
wast
caus
drinkabl
water
shortag
certain
region
world
expect
mass
migrat
could
chang
pattern
infect
drive
outbreak
migrant
travers
tropic
forest
feed
meat
game
carcass
two
scenario
could
envis
emerg
zoonot
infecti
diseas
sever
predict
model
develop
evalu
impact
climat
chang
emerg
infecti
diseas
climex
dymex
miasma
model
nevertheless
remain
difficult
predict
pathogen
behavior
deviat
typic
pattern
climat
chang
primarili
affect
vectorborn
diseas
increas
rate
reproduct
bite
shorten
incub
period
pathogen
carri
tick
gain
spread
mediterranean
basin
northern
eastern
europ
well
appear
higher
altitud
increas
surviv
densiti
activ
also
report
follow
shorter
milder
winter
climat
chang
also
result
day
activ
per
year
mosquito
temperatur
rise
parasit
viabl
within
region
rang
mediterranean
tropic
zone
balkan
russia
scandinavia
uk
tick
flea
temperatur
rel
humid
optim
prolifer
activ
throughout
year
exampl
dengu
fever
usual
limit
tropic
latitud
low
altitud
sinc
mosquito
egg
larva
lose
viabil
sustain
low
temperatur
unusu
warm
summer
howev
dengu
report
high
sea
level
warmer
temperatur
also
result
smaller
adult
mosquito
need
bite
frequent
feed
abl
lay
egg
thu
increas
rate
transmiss
contrast
incid
malaria
follow
mix
pattern
increas
decreas
along
recent
decad
comput
model
fail
predict
spread
explan
part
climat
chang
also
result
diminish
surviv
vector
warm
affect
surviv
parasit
vector
part
effect
climat
chang
nonlinear
complex
frequenc
emerg
vectorborn
infect
vari
per
chang
land
use
human
activ
intervent
maneuv
erad
vector
prevent
transmiss
human
drug
treatment
vaccin
ecolog
econom
chang
may
bring
togeth
rodent
human
hunt
activ
may
chang
vector
distribut
largescal
anim
movement
impact
diseas
distribut
impoverish
citi
overcrowd
slum
also
reforest
golf
club
develop
urban
rural
suburb
facilit
exposur
tick
rodent
mani
patient
pidd
requir
immunoglobulin
replac
immunoglobulin
product
demonstr
improv
outcom
hepat
measl
least
neutral
antibodi
present
direct
rsv
group
b
streptococci
rais
three
distinct
issu
patient
difficulti
diagnosi
infect
travel
local
produc
immunoglobulin
may
antibodi
titer
local
infect
typic
countri
safeti
concern
local
produc
immunoglobulin
patient
resid
locat
long
enough
requir
immunoglobulin
local
provid
decis
use
local
produc
immunoglobulin
product
provid
superior
prevent
infect
compar
patient
usual
product
limit
data
subject
serolog
diagnost
test
patient
immunoglobulin
therapi
address
term
issu
relat
lack
specif
antibodi
produc
patient
potenti
infect
convers
also
issu
patient
arriv
countri
signific
occurr
infect
unusu
current
countri
may
igg
antibodi
infect
simpli
immunoglobulin
product
reflect
true
infecti
event
patient
lead
diagnost
confus
serolog
test
demonstr
presenc
antibodi
due
infus
product
patient
often
ask
immunoglobulin
product
countri
held
rigor
standard
home
countri
today
commerci
produc
immunoglobulin
safe
tightli
regul
commerci
produc
immunoglobulin
around
world
one
timetest
viral
inactiv
procedur
nanofiltr
capryl
absorpt
pasteur
solventdeterg
vapor
heat
low
ph
treatment
procedur
uniformli
inactiv
envelop
virus
mani
emerg
virus
specif
test
abil
withstand
purif
process
much
learn
sinc
transmiss
hepat
c
virus
immunoglobulin
product
earli
nevertheless
vigil
import
counterfeit
immunoglobulin
identifi
therefor
patient
ensur
receiv
brand
name
product
travel
subject
whether
patient
interest
would
best
serv
use
local
immunoglobulin
product
antibodi
pathogen
preval
commun
home
physician
ship
usual
product
patient
known
toler
hotli
debat
patient
histori
intoler
immunoglobulin
product
switch
unless
necessari
howev
compel
reason
consid
local
produc
product
patient
foreign
countri
extend
period
known
antibodi
west
nile
viru
track
distribut
viru
emerg
sever
area
titer
product
use
donor
usa
higher
neutral
titer
west
nile
viru
use
donor
europ
although
differ
titer
lot
usa
similarli
protect
antibodi
concern
pathogen
may
optim
local
produc
immunoglobulin
critic
inquir
plasma
sourc
deriv
countri
util
immunoglobulin
produc
europ
usa
differ
name
ensur
plasma
pool
come
differ
countri
lot
immunoglobulin
produc
plasma
donor
infrastructur
support
endeavor
easi
establish
geograph
area
serolog
test
commonli
use
diagnosi
infect
approach
reli
upon
detect
quantit
antibodi
made
host
specif
pathogen
presenc
igm
antibodi
specif
pathogen
indic
recent
infect
igg
antibodi
specif
pathogen
indic
past
infect
importantli
serolog
test
appli
diagnosi
infect
host
mount
specif
antibodi
respons
pathogen
convers
serolog
reli
upon
diagnos
infect
set
immun
defici
impair
specif
antibodi
respons
case
primari
antibodi
defici
cellular
immun
defici
combin
immun
defici
secondari
immun
defici
affect
andor
b
cell
function
situat
caus
pathogen
must
identifi
altern
mean
cultur
organ
antigen
detect
molecular
approach
nucleic
acid
hybrid
nucleic
acid
sequenc
oligonucleotid
probe
array
molecular
approach
particularli
relev
diagnosi
infect
patient
pidd
signal
target
amplif
techniqu
coupl
nucleic
acid
hybrid
probe
assay
allow
detect
pathogen
dna
rna
present
small
amount
clinic
sampl
patient
pidd
vaccin
could
play
import
role
prevent
infect
vaccineprevent
diseas
even
pidd
patient
may
gener
protect
respons
decis
immun
patient
depend
type
sever
pidd
well
type
vaccin
administ
live
inactiv
tabl
gener
inactiv
vaccin
safe
pidd
patient
immun
live
attenu
vaccin
known
hazard
patient
seriou
immunodefici
cell
b
cell
phagocyt
cell
origin
tabl
less
sever
pidd
vaccin
induc
adequ
protect
healthi
individu
efficaci
may
reduc
note
immunoglobulin
replac
therapi
induc
passiv
immun
protect
vaccineprevent
infect
measl
mump
rubella
mmr
varicella
addit
live
viral
vaccin
greatli
reduc
efficaci
immunoglobulin
replac
therefor
vaccin
administr
patient
receiv
regular
immunoglobulin
replac
treatment
withheld
least
month
depend
dose
cessat
treatment
cessat
vaccin
safe
addit
pidd
patient
receiv
hematopoiet
stem
cell
transplant
incomplet
immun
reconstitut
immunosuppress
receiv
live
attenu
vaccin
gener
decis
administ
live
viral
vaccin
made
clinic
immunolog
expert
develop
countri
polio
still
endem
oral
polio
vaccin
essenti
erad
diseas
utmost
import
pidd
patient
famili
member
receiv
live
oral
polio
opv
report
prolong
excret
viru
month
even
year
addit
vaccineassoci
paralyt
polio
real
risk
pidd
patient
famili
member
receiv
inactiv
polio
vaccin
ipv
instead
opv
similarli
hazard
administ
bacillu
calmetteguerin
bcg
vaccin
pidd
patient
document
seri
bcg
vaccin
sever
combin
immunodefici
scid
patient
center
countri
scid
patient
develop
dissemin
bcg
infect
worst
outcom
patient
chronic
granulomat
diseas
vaccin
bcg
also
develop
local
dissemin
bcg
infect
recent
vaccin
strain
rubella
viru
found
associ
skin
granuloma
pidd
patient
sibl
household
contact
patient
suspect
diagnos
pidd
receiv
nation
immun
schedul
vaccin
ipv
substitut
op
famili
antibodydefici
patient
exist
yearli
influenza
vaccin
famili
member
recommend
order
reduc
risk
householdsoci
transmiss
diseas
routin
vaccin
reduc
incid
occasion
experi
resurg
time
econom
hardship
reduc
attent
vaccin
diphtheria
current
seen
venezuela
reason
war
disrupt
health
infrastructur
common
reason
resurg
vaccineprevent
diseas
set
antivaccin
sentiment
led
outbreak
diphtheria
measl
mump
addit
consider
countri
provid
level
vaccin
therefor
vaccineprevent
ill
still
seen
region
outbreak
repres
signific
risk
patient
pidd
univers
consider
patient
pidd
concern
antibiot
resist
vari
dramat
around
world
certain
high
impact
infect
emerg
antibiot
resist
pattern
discuss
antimicrobi
resist
occur
natur
misus
overus
antimicrobi
acceler
process
nearli
everi
countri
antibiot
overus
misus
peopl
anim
lead
antibiot
resist
everi
countri
key
resist
pattern
common
bacteria
includ
emerg
carbapenemresist
klebsiella
pneumonia
around
world
high
frequenc
resist
due
differ
mechan
mediterranean
greec
itali
turkey
endem
spread
pathogen
carbapenemresist
strain
among
genera
enterobacteriacea
also
recogn
particularli
common
greec
found
wide
distribut
new
delhi
metallobetalactamasemedi
resist
endem
indian
subcontin
becom
increasingli
spread
worldwid
grow
concern
common
caus
urinari
tract
infect
colistin
recours
carbapenemresist
enterobacteriacea
colistin
resist
recent
emerg
small
outbreak
throughout
world
case
infect
essenti
untreat
fluoroquinoloneresist
escherichia
coli
common
caus
urinari
tract
infect
account
half
isol
asian
countri
emerg
resist
antibiot
gramposit
pathogen
becom
major
intern
problem
fewer
even
sometim
effect
antimicrobi
agent
avail
infect
caus
bacteria
methicillinresist
staphylococcu
aureu
common
mani
countri
fact
spawn
nomenclatur
recogn
gener
public
mrsa
sever
studi
report
resist
newer
antimicrobi
agent
like
linezolid
vancomycin
teicoplanin
daptomycin
thu
far
isol
appear
uncommon
found
isol
brazil
china
ireland
itali
nearli
undetect
rate
elsewher
vancomycinresist
enterococcu
vre
grow
frequenc
caus
primari
bacteremia
immunocompromis
individu
key
messag
antibiot
resist
increas
gener
travel
alert
resist
commonli
encount
organ
antibiot
prophylaxi
requir
prophylaxi
adjust
neisseria
gonorrhoea
specif
organ
resist
becom
especi
problemat
progress
develop
resist
virtual
antimicrobi
agent
sinc
introduct
sulfonamid
current
treatment
guidelin
recommend
dual
antimicrobi
therapi
ceftriaxon
mg
plu
azithromycin
g
firstlin
regimen
although
dual
therapi
effect
develop
concomit
ceftriaxon
azithromycin
resist
like
emerg
risk
untreat
n
gonorrhoea
demand
better
global
antimicrobi
surveil
system
clinic
trial
combin
therapi
exist
drug
well
novel
agent
monotherapi
develop
gonococc
vaccin
pidd
patient
guidanc
barrier
method
prevent
sexual
transmit
diseas
part
pretravel
counsel
mycobacteria
tuberculosi
mtb
ageold
pathogen
emerg
resist
drugresist
tb
fuel
hiv
epidem
global
threat
estim
new
case
multidrugresist
tb
mdrtb
addit
new
case
rifampinresist
tb
rrtb
would
also
requir
mdrtb
treatment
treatment
mdrtb
mycobacterium
bovi
diseas
beyond
scope
text
reader
refer
recent
mdr
treatment
guidelin
region
world
mdr
tb
includ
region
azerbaijan
kazakhstan
russia
uzbekistan
china
georgia
eastern
europ
extens
drugresist
tb
xdr
tb
refer
mtb
resist
isoniazid
rifampin
fluoroquinolon
least
one
secondlin
drug
xdr
tb
report
countri
averag
patient
mdr
tb
xdr
tb
true
type
mtb
xdr
tb
contagi
small
outbreak
relat
personperson
transmiss
report
nontubercul
mycobacteria
ntm
caus
signific
system
infect
patient
defect
axi
well
defici
caus
signific
pulmonari
infect
pidd
patient
bronchiectasi
compar
tb
ntm
acquir
environ
persontoperson
transmiss
therefor
acquisit
antibioticresist
strain
less
common
howev
individu
pidd
ntm
diseas
often
chronic
difficult
erad
resist
easili
develop
therapi
use
combin
antibiot
essenti
consult
familiar
treatment
treatment
refractori
ntm
diseas
recommend
aspergillu
speci
ubiquit
inhal
mold
worldwid
distribut
caus
opportunist
infect
immunocompromis
patient
aspergillosi
also
occur
pidd
associ
quantit
andor
qualit
phagocyt
defect
develop
frequent
chronic
granulomat
diseas
cgd
patient
preval
seen
less
often
patient
defici
defici
congenit
neutropenia
syndrom
upon
inhal
aspergillu
speci
caus
invas
pulmonari
diseas
suscept
host
except
defici
aspergillosi
predilect
extrapulmonari
tissu
spare
lung
diagnosi
establish
fungal
cultur
andor
histopatholog
show
acuteangl
septat
hypha
andor
detect
galactomannan
aspergillu
cell
wall
compon
releas
invas
infect
serum
bronchoalveolar
lavag
fluid
azolesuscept
aspergillu
fumigatu
still
common
infect
speci
pidd
patient
emerg
azoleresist
fumigatu
nonfumigatu
aspergillu
speci
underscor
import
high
index
suspicion
patient
respond
frontlin
voriconazol
treatment
advent
fungal
molecular
diagnost
demonstr
patient
pidd
prone
infect
uncommon
lowvirul
aspergillu
speci
intrins
resist
azol
antifung
agent
infect
patient
iatrogen
immunosuppress
primarili
includ
aspergillu
viridinutan
aspergillu
tanneri
neosartorya
udagawa
pose
major
diagnost
therapeut
challeng
due
impair
sporul
propens
contigu
distant
tissu
spread
respect
addit
acquir
azol
resist
fumigatu
seen
patient
longterm
exposur
azol
drug
use
treatment
andor
prophylaxi
azol
resist
strain
predominantli
caus
point
mutat
lanosterol
gene
encod
protein
primari
target
azol
drug
importantli
infect
azoleresist
fumigatu
strain
without
prior
exposur
patient
azol
antifung
recent
emerg
import
global
health
concern
due
widespread
use
sterol
demethylas
inhibitor
fungicid
agricultur
result
crossresist
triazol
antifung
use
clinic
practic
fungicidedriven
azoleresist
environment
aspergillu
strain
first
observ
netherland
sinc
document
part
europ
south
north
america
middl
east
australia
africa
asia
preval
azoleresist
aspergillu
strain
among
clinic
aspergillu
strain
recov
patient
european
countri
report
alarmingli
area
recov
strain
exhibit
azol
resist
emerg
aspergillu
environment
strain
pose
seriou
threat
treatment
immunosuppress
patient
mortal
rate
high
seen
due
delay
diagnosi
suboptim
treatment
azol
antifung
although
prospect
data
exist
treatment
patient
resist
fungi
use
amphotericin
band
echinocandinbas
regimen
prefer
azol
absenc
azol
lack
altern
oral
antifung
agent
particularli
challeng
pidd
patient
cgd
requir
longterm
suppress
antifung
treatment
candida
speci
commens
yeast
fungi
colon
mucos
surfac
healthi
individu
perturb
immun
andor
microbiota
occur
candida
caus
opportunist
mucos
system
infect
depend
clearli
segreg
immun
respons
host
defens
specif
cell
program
critic
mucos
phagocyt
system
immun
inde
proport
patient
cgd
complet
myeloperoxidas
defici
develop
system
mucos
candidiasi
wherea
patient
monogen
syndrom
chronic
mucocutan
candidiasi
due
mutat
signal
pathway
gene
advers
affect
differenti
rorc
air
develop
system
candidiasi
known
pidd
date
result
combin
mucos
system
candida
infect
suscept
defici
system
candidiasi
patient
predilect
central
nervou
system
associ
brainspecif
impair
recruit
effector
function
neutrophil
diagnosi
candida
infect
establish
cultur
azolesuscept
candida
albican
still
common
infect
speci
pidd
patient
howev
emerg
azoleresist
c
albican
uncommon
chronic
azol
use
make
longterm
therapi
challeng
due
lack
altern
oral
antifung
treatment
option
beyond
c
albican
nonalbican
candida
speci
rare
infect
pidd
patient
intrins
resist
azol
antifung
includ
candida
glabrata
candida
krusei
recent
candida
auri
emerg
global
public
health
concern
due
resist
antifung
drug
high
virul
potenti
propens
health
careassoci
horizont
transmiss
outbreak
health
care
set
persist
human
skin
hospit
environ
inher
resili
antisept
misidentif
routin
biochem
method
yeast
often
candida
haemulonii
also
candida
famata
rhodotorula
glutini
saccharomyc
cerevisia
c
auri
first
recov
ear
canal
patient
japan
sinc
report
caus
lifethreaten
infect
hospit
outbreak
europ
asia
africa
middl
east
south
north
america
report
strain
c
auri
intrins
resist
fluconazol
triazol
antifung
agent
signific
proport
strain
elev
minimum
inhibitori
concentr
amphotericin
b
echinocandin
strain
reportedli
resist
three
class
azol
polyen
echinocandin
avoid
azol
antifung
import
c
aurisinfect
patient
echinocandinor
amphotericin
bbase
regimen
prefer
guid
strainspecif
vitro
suscept
pattern
section
vectorborn
infect
major
focu
review
infect
often
sever
immunocompromis
individu
mitig
strategi
consid
even
absenc
defin
medic
treatment
infect
prevent
mosquito
bite
depend
somewhat
endem
speci
gener
use
mosquito
repel
deet
oil
lemon
eucalyptu
picaridin
import
use
long
sleev
long
pant
affect
area
deet
picaridin
safe
pregnanc
data
support
greater
efficaci
air
condit
fan
tend
keep
mosquito
away
net
night
essenti
mosquitopron
area
lightcolor
cloth
less
attract
mosquito
dark
cloth
scent
deterg
use
dryer
sheet
tend
attract
mosquito
henc
avoid
aed
speci
prefer
bite
indoor
thrive
urban
area
small
puddl
water
bite
frequent
around
dawn
dusk
anophel
speci
similar
behavior
culex
mosquito
contrast
bite
primarili
night
tick
fli
bite
prevent
focus
physic
chemic
prevent
tick
physic
inspect
bite
tick
also
incorpor
arthropodborn
virus
arbovirus
transmit
human
bite
infect
insect
mosquito
tick
sand
fli
midg
arbovirus
transmit
blood
transfus
organ
transplant
perinat
transmiss
consumpt
unpasteur
dairi
product
breastfeed
arbovirus
caus
human
diseas
arbovir
infect
asymptomat
infecti
manifest
rang
mild
febril
ill
sever
enceph
arbovir
infect
often
categor
two
primari
group
neuroinvas
diseas
nonneuroinvas
diseas
tabl
list
encephalitigen
virus
febrilehemorrhag
diseas
caus
virus
section
highlight
west
nile
viru
common
encephalitogen
arbovirus
west
nile
viru
singlestrand
mosquitoborn
rna
viru
famili
flavivirida
natur
transmiss
cycl
viru
occur
culex
mosquito
bird
human
hors
deadend
host
viru
common
mode
transmiss
human
bite
infect
mosquito
less
common
mode
transmiss
includ
blood
transfus
organ
transplant
occup
exposur
laboratori
mothertochild
transmiss
pregnanc
childbirth
breastfeed
west
nile
viru
diagnos
peopl
usa
slightli
half
neuroinvas
diseas
sinc
peopl
usa
infect
also
common
africa
europ
asia
infect
west
nile
viru
asymptomat
individu
incub
period
last
day
howev
significantli
longer
immunocompromis
host
clinic
manifest
follow
infect
develop
infect
includ
fever
headach
myalgia
arthralgia
vomit
rash
sever
neuroinvas
diseas
lead
mening
enceph
flaccid
paralysi
develop
less
infect
individu
overal
case
fatal
approxim
disproportion
high
mortal
patient
enceph
myeliti
diagnosi
west
nile
viru
rest
demonstr
specif
antibodi
respons
especi
specif
igm
antibodi
serum
csf
infect
individu
enzym
immunoassay
plaqu
reduct
neutral
test
differenti
crossreact
antibodi
detect
viru
csf
blood
tissu
specimen
cultur
pcr
particularli
use
immunosuppress
individu
may
impair
serolog
respons
west
nile
viru
report
context
primari
secondari
immunodefici
sever
neurolog
manifest
report
hivposit
individu
individu
receiv
immunosuppress
therapi
includ
rituximab
individu
pidd
infect
wnv
report
individu
common
variabl
immunodefici
idiopath
lymphopenia
defici
case
probabl
good
syndrom
individu
antibodi
defect
neutropenia
impair
cell
respons
potenti
increas
risk
sever
manifest
wnv
diseas
includ
sever
neurolog
involv
section
highlight
four
import
nonneuroinvas
arbovirus
base
current
geograph
distribut
dengu
yellow
fever
zika
chikungunya
tabl
approxim
countriesterritori
report
local
transmiss
chikungunya
dengu
virus
dengu
due
infect
one
four
dengu
viru
serotyp
transmit
mosquito
typic
aed
aegypti
febril
ill
affect
age
symptom
appear
day
infect
bite
symptom
rang
mild
high
fever
sever
headach
musculoskelet
pain
rash
sever
dengu
also
known
dengu
hemorrhag
fever
occur
case
character
fever
abdomin
pain
persist
vomit
bleed
breath
difficulti
potenti
lethal
complic
paradox
main
risk
factor
dengu
hemorrhag
fever
preexist
antibodi
earli
clinic
diagnosi
comprehens
manag
experienc
clinician
increas
surviv
dengu
ubiquit
throughout
tropic
highest
infect
rate
america
asia
dengu
endem
countri
caus
million
infect
year
death
mainli
among
children
half
world
popul
inhabit
area
risk
dengu
infect
presenc
aegypti
countri
potenti
put
almost
whole
world
risk
becom
infect
viru
pcr
wide
use
serolog
method
diagnos
dengu
immun
one
serotyp
confer
protect
three
serotyp
heterolog
antibodi
may
risk
factor
hemorrhag
dengu
natur
histori
dengu
studi
hiv
patient
hiv
appear
increas
sever
report
patient
pidd
dengu
howev
dengu
infect
solid
transplant
report
patient
sever
complic
suggest
cell
compromis
pidd
could
risk
sever
diseas
antivir
medic
util
dengu
viru
care
patient
hemorrhag
diseas
requir
meticul
approach
fluid
coagul
statu
one
dengu
vaccin
regist
sever
countri
cydtdv
individu
year
old
live
attenu
recombin
tetraval
vaccin
backbon
attenu
yellow
fever
viru
genom
prm
e
gene
encod
protein
four
wildtyp
dengu
virus
suggest
use
region
seropreval
dengu
viru
serotyp
greater
recommend
hivinfect
immunocompromis
individu
pregnant
lactat
women
peopl
infect
yellow
fever
viru
ill
symptom
yellow
fever
includ
sudden
onset
fever
chill
headach
musculoskelet
pain
nausea
vomit
fatigu
weak
incub
period
typic
day
symptom
may
appear
return
travel
peopl
improv
initi
present
case
progress
develop
sever
form
diseas
usual
day
presum
recoveri
sever
form
character
high
fever
jaundic
bleed
eventu
shock
failur
multipl
organ
yellow
fever
viru
rna
viru
belong
genu
flaviviru
transmit
mosquito
bite
infect
primat
wide
distribut
equatori
tropic
aed
speci
mosquito
primarili
respons
transmiss
larg
epidem
yellow
fever
occur
infect
enter
heavili
popul
area
high
mosquito
densiti
peopl
littl
immun
west
africa
undergon
largescal
vaccin
campaign
impress
result
yellow
fever
uncommon
west
africa
serolog
test
yellow
fever
diagnost
standard
pcr
perform
tissu
sampl
publish
studi
yellow
fever
immunocompromis
peopl
elderli
young
peopl
autoimmun
diseas
postthymectomi
risk
attenu
vaccin
strain
thu
seem
like
immunodefici
would
associ
sever
wildtyp
diseas
current
specif
antivir
drug
yellow
fever
exist
treatment
dehydr
liver
kidney
failur
fever
improv
outcom
yellow
fever
vaccin
highli
effect
howev
immunodefici
patient
receiv
infect
zika
viru
often
asymptomat
repres
mild
infect
symptom
zika
viru
detect
urin
semen
saliva
infect
individu
transmiss
transfus
sexual
relat
report
also
detect
breast
milk
breastfeedingassoci
transmiss
report
far
contact
highli
infecti
bodi
fluid
patient
sever
zika
infect
also
suggest
possibl
mode
transmiss
tremend
import
presenc
prolong
shed
zika
viru
congenit
infect
newborn
main
public
health
risk
zika
viru
microcephali
newborn
infect
mother
zika
viru
capabl
infect
human
neural
progenitor
cell
vitro
infect
result
disrupt
cell
cycl
increas
cell
death
attenu
neuron
growth
zika
thought
major
risk
peopl
pidd
base
experi
hiv
patient
recognit
zika
recent
known
specif
treatment
zika
howev
import
effort
develop
vaccin
chikungunya
fever
acut
febril
ill
caus
alphaviru
chikungunya
viru
incub
period
usual
day
bite
infect
aed
mosquito
abrupt
onset
high
fever
fever
biphas
sever
polyarthraligia
develop
onset
fever
joint
pain
affect
joint
pattern
usual
symmetr
true
acut
arthriti
uncommon
proport
infect
peopl
rash
vari
across
studi
seen
rash
appear
fever
truncal
maculopapular
type
rash
cervic
adenopathi
anoth
common
featur
infect
death
uncommon
chikungunya
seriou
complic
myocard
seen
half
patient
report
continu
joint
symptom
year
acut
ill
longterm
joint
symptom
chikungunya
origin
centraleast
africa
forest
viru
circul
aed
mosquito
nonhuman
primat
urban
center
viru
circul
human
mosquito
similar
pattern
dengu
period
urban
outbreak
asia
africa
sinc
acceler
spread
sinc
import
consider
period
outbreak
high
attack
rate
popul
area
risk
current
east
africa
central
africa
la
reunion
india
southeast
asia
diagnost
test
util
pcr
serolog
threat
immunodefici
patient
entir
clear
provoc
case
immunocompromis
appear
associ
fewer
joint
symptom
two
patient
medic
immun
compromis
sever
diseas
suggest
present
may
atyp
cours
may
sever
immunodefici
peopl
treatment
support
although
chloroquin
acyclovir
ribavirin
steroid
limit
preclin
data
support
clinic
trial
babesia
microti
main
speci
usa
infect
asymptomat
mani
peopl
develop
fever
chill
headach
myalgia
anorexia
nausea
fatigu
babesiosi
often
caus
hemolyt
anemia
b
microti
spread
ixod
scapulari
tick
usa
babesia
divergen
main
speci
europ
spread
ixod
ricinu
symptom
begin
week
bite
infect
tick
b
divergen
higher
mortal
rate
greater
symptomatolog
compar
b
microti
main
geograph
area
involv
coastal
eastern
usa
cattl
breed
area
throughout
europ
diagnosi
usual
inspect
blood
smear
serolog
pcr
test
develop
immunodefici
asplenia
older
age
recogn
risk
factor
sever
diseas
even
death
thu
congenit
asplenia
would
consid
major
risk
sever
diseas
combin
atovaquon
azithromycin
gener
use
therapi
although
clindamycin
quinin
use
success
patient
sever
ill
treat
exchang
transfus
five
differ
type
plasmodium
plasmodium
falciparum
plasmodium
vivax
plasmodium
oval
plasmodium
malaria
plasmodium
knowelsi
infect
human
malaria
transmit
primarili
femal
anophel
mosquito
symptom
vari
depend
type
plasmodium
involv
usual
includ
high
fever
chill
headach
case
ill
progress
sever
anemia
kidney
respiratori
failur
death
incub
period
typic
rang
day
p
falciparum
day
p
vivax
p
oval
day
p
malaria
p
vivax
p
oval
infect
relaps
occur
month
even
year
without
symptom
p
vivax
p
oval
dormant
liver
stage
parasit
must
specif
erad
medic
therapi
malaria
global
health
concern
throughout
histori
lead
caus
death
diseas
across
mani
tropic
subtrop
countri
last
year
new
control
measur
reduc
malaria
half
democrat
republ
congo
nigeria
account
estim
total
malaria
death
global
high
rate
malaria
seen
india
well
nevertheless
malaria
exist
tropic
region
america
africa
asia
diagnosi
malaria
depend
demonstr
parasit
blood
usual
microscopi
threat
immunodefici
patient
entir
clear
patient
hiv
seem
addit
burden
diseas
increas
placent
malaria
suggest
cell
central
defens
malaria
asplenia
known
risk
factor
sever
malaria
antibodi
appear
protect
patholog
treatment
prophylaxi
depend
region
world
parasit
resist
highli
variabl
highli
dynam
therefor
best
consult
infecti
diseas
specialist
familiar
prophylaxi
travel
treatment
acut
case
leishmaniasi
due
infect
oblig
macrophag
intracellular
protozoa
genu
leishmania
caus
spectrum
diseas
rang
cutan
ulcer
mucos
diseas
sever
form
viscer
leishmaniasi
vl
liver
spleen
bone
marrow
major
site
parasit
growth
diseas
patholog
vl
pure
cutan
leishmaniasi
often
caus
leishmania
major
leishmania
tropica
leishmania
aethiopica
leishmania
infantum
parasit
belong
leishmania
mexicana
complex
leishmania
braziliensi
complex
leishmania
guyanensi
complex
mucocutan
diseas
often
due
l
braziliensi
complex
leishmania
panamensi
leishmania
amazonensi
rare
leishmania
guyanensi
vl
often
caus
leishmania
donovani
leishmania
infantum
previous
l
chagasi
cutan
leishmaniasi
mani
variat
often
ulcer
develop
indol
papul
incub
period
rang
week
month
ulcer
usual
heal
within
month
year
mild
adenopathi
mucocutan
leishmaniasi
follow
cutan
ulcer
caus
l
braziliensi
parasit
oral
respiratori
mucosa
often
involv
granulomat
lesion
may
extrem
destruct
vl
associ
fever
lymphadenopathi
hepatosplenomegali
wast
hypoalbuminemia
pancytopenia
pictur
evolv
month
year
secondari
immun
defici
due
pancytopenia
epidemiolog
chang
dramat
impact
climat
chang
sand
fli
spread
parasit
affect
temperatur
rainfal
endem
region
leishmania
patchi
distribut
due
microecolog
factor
poverti
demonstr
major
risk
factor
leishmaniasi
estim
half
million
new
case
vl
occur
everi
year
major
resourcepoor
countri
bangladesh
nepal
india
sudan
ethiopia
brazil
emerg
resist
antimonybas
drug
also
led
major
resurg
diseas
primari
reservoir
leishmania
forest
rodent
dog
increasingli
import
grow
spread
leishmania
due
combin
factor
countri
report
case
immunodefici
patient
suscept
infect
relaps
occur
frequent
risk
develop
vl
estim
time
higher
hivinfect
nonhivinfect
individu
patient
higher
rate
treatment
failur
ill
often
take
prolong
chronic
cours
higher
mortal
rate
similar
pictur
seen
patient
vlinfect
postkidney
transplant
dendrit
cell
cell
gener
reactiv
oxygen
speci
shown
essenti
parasit
control
pidd
impair
product
associ
sever
diseas
patient
defici
associ
poor
product
chronic
leishmania
die
spite
aggress
treatment
vl
report
cgd
patient
six
cgd
patient
infect
leishmania
develop
hemophagocyt
syndrom
poor
outcom
one
diagnosi
leishmaniasi
usual
visual
inspect
parasit
immunofluoresc
microscopi
direct
agglutin
skin
test
pcr
use
treatment
longterm
difficult
emerg
resist
firstlin
treatment
increasingli
problemat
pentaval
antimoni
mainstay
treatment
countri
liposom
amphotericin
wide
use
resist
occur
newer
drug
favor
side
effect
profil
use
certain
geograph
set
miltefosin
paromycin
sitamaquin
rickettsia
small
gramneg
bacteria
oblig
intracellular
parasit
primari
target
human
appear
endotheli
cell
subsequ
thrombosi
clinic
present
vascul
rickettsiacea
famili
origin
defin
nonspecif
phenotyp
characterist
reclassifi
differ
strain
subspeci
base
gene
sequenc
genet
phylogeni
tabl
clinic
present
rickettsi
diseas
vari
classic
triad
fever
rash
headach
still
provid
major
clue
diagnosi
howev
rash
obligatori
sign
incid
rash
rang
rickettsia
conorii
infect
rickettsia
rickettsii
rickettsia
africa
less
case
anaplasma
phagocytophilum
infect
therefor
fever
patient
exposur
potenti
vector
rais
concern
rickettsi
diseas
especi
also
evid
rash
inocul
eschar
local
lymphadenopathi
addit
support
laboratori
find
includ
neutropenia
thrombocytopenia
increas
liver
transaminas
geograph
distribut
rickettsios
ehrlichios
mostli
depend
vector
distribut
louseborn
fleaborn
worldwid
reflect
worldwid
distribut
lice
flea
tendenc
parasit
poor
peopl
cold
place
characterist
war
tick
hand
depend
environ
worldwid
distribut
except
dog
tick
vector
r
conorii
asia
north
africa
r
rickettsii
usa
rickettsia
massiia
erhlichia
cani
worldwid
tickborn
diseas
restrict
area
world
correl
distribut
vector
reason
anticip
climat
environment
chang
affect
vector
distribut
reservoir
host
henc
geographi
epidemiolog
tickborn
diseas
diagnosi
present
challeng
extrem
difficult
grow
organ
cultur
immunohistochemistri
pcr
help
sever
rickettsi
diseas
vari
caus
agent
host
r
rickettsii
rickettsia
prowazekii
orienta
tsutsugamushi
consid
pathogen
host
factor
although
sever
fatal
case
describ
healthi
immunocompet
host
evid
suggest
children
age
immunocompromis
host
either
secondari
hematolog
malign
immunosuppress
treatment
organ
transplant
hiv
infect
greater
risk
develop
sever
diseas
higher
case
fatal
rate
rickettsiacea
intracellular
pathogen
one
could
expect
increas
risk
sever
diseas
pidd
abnorm
cell
function
five
day
doxycyclin
prefer
treatment
nonpregn
adult
children
treatment
delay
await
diagnost
test
given
children
despit
minim
risk
dental
stain
altern
treatment
includ
azithromycin
mild
diseas
chloramphenicol
pregnant
women
anaplasma
intracellular
bacterium
infect
wild
domest
mammal
includ
man
phagocytophilum
formerli
known
human
granulocytotrop
ehrlighiosi
known
human
granulocytotrop
anaplasmosi
e
chaffeensi
infect
monocyt
caus
human
monocyt
ehrlichiosi
anaplasma
ehrlichia
histor
cycl
within
nonhuman
enzoot
host
man
becom
infect
increas
interact
environ
ehrlichia
anaplasma
transmit
ixod
speci
tick
rang
includ
eastern
usa
south
central
usa
scatter
region
europ
far
north
sweden
infect
seen
human
southern
hemispher
report
organ
identifi
less
common
mode
transmiss
transfus
symptom
ehrlichia
anaplasma
infect
similar
abrupt
onset
influenzalik
ill
occur
day
tick
bite
ehrlichia
caus
mild
rash
adult
children
rash
uncommon
anaplasma
infect
highli
suggest
laboratori
featur
leukopenia
thrombocytopenia
mortal
gener
popul
appear
icu
admiss
uncommon
hemophagocytosi
describ
anaplasma
ehrlichia
infect
sever
set
immun
compromis
includ
asplenia
diagnosi
typic
made
pcr
doxycyclin
recommend
treatment
intracellular
inclus
seen
cbc
smear
often
anaplasma
ehrlichia
uncommon
well
describ
facet
infect
tick
vector
also
transmit
borrelia
burgdorferi
babesia
microti
simultan
infect
multipl
organ
occur
c
burnetii
highli
pleomorph
gramneg
coccobacillu
caus
agent
q
fever
q
fever
zoonosi
common
reservoir
cattl
sheep
goat
mani
anim
infect
c
burnetii
infect
domest
anim
shed
organ
urin
fece
milk
especi
birth
product
pathogen
surviv
within
phagolysosom
host
cell
spore
stage
describ
spore
stage
explain
abil
c
burnetii
surviv
unfavor
environment
condit
environment
risk
month
year
shed
infect
anim
q
fever
consid
occup
diseas
affect
peopl
direct
contact
infect
anim
howev
indirect
contact
exposur
contamin
anim
product
also
describ
caus
diseas
outbreak
human
infect
inhal
contamin
aerosol
follow
averag
incub
period
day
infect
patient
present
sever
headach
fever
chill
fatigu
myalgia
sign
symptom
depend
organ
involv
contrast
rickettsi
diseas
describ
rash
rare
occur
earli
stage
diseas
c
burnetii
caus
rang
clinic
symptom
selflimit
febril
ill
probabl
common
form
q
fever
pneumonia
either
atyp
sever
also
common
part
acut
q
fever
syndrom
contrast
varieti
manifest
recogn
chronic
q
fever
includ
endocard
endovascular
infect
osteomyel
hepat
interstiti
pulmonari
fibrosi
prolong
fever
purpur
vasculit
rash
q
fever
diagnosi
base
serolog
test
indirect
immunofluoresc
best
differenti
acut
chronic
q
fever
high
antiphas
antigen
titer
treatment
choic
acut
q
fever
doxycyclin
cotrimoxazol
chloramphenicol
rifampin
accept
altern
agreement
treatment
q
fever
endocard
combin
doxycyclin
either
fluoroquinolon
hydroxychloroquin
recommend
also
controversi
regard
durat
treatment
rang
year
indefinit
treatment
old
evid
suggest
q
fever
common
immunocompromis
patient
french
studi
show
higher
incid
antibodi
c
burnetii
hiv
posit
compar
hivneg
patient
vs
addit
hospit
patient
hiv
posit
suggest
frequent
symptomat
diseas
smaller
similar
studi
perform
central
africa
fail
show
increas
incid
seroposit
hivposit
patient
two
case
report
describ
sever
diseas
immunocompromis
patient
first
case
fatal
q
fever
diseas
male
cgd
patient
treat
broad
spectrum
antibiot
without
coverag
q
fever
second
case
asplen
male
present
fever
jaundic
encephalopathi
diagnos
acut
q
fever
patient
success
treat
two
case
report
could
suggest
suscept
case
phagocyt
disord
bartonellacea
fastidi
facult
intracellular
gramneg
bacilli
tabl
speci
infect
primarili
nonhuman
anim
case
human
consid
incident
host
document
common
human
pathogen
includ
bartonella
bacilliformi
bartonella
hensela
bartonella
quintana
believ
human
primari
mammalian
reservoir
b
quintana
infect
occur
inocul
bartonellainfect
arthropod
fece
break
skin
epidemiolog
bartonella
infect
human
follow
distribut
vector
infect
b
bacilliformi
follow
distribut
sand
fli
vector
lutzomya
confin
and
mountain
peru
ecuador
colombia
height
human
bodi
lous
pediculu
humanu
vector
b
quintana
explain
global
distribut
pathogen
worldwid
outbreak
trench
fever
mostli
condit
poor
sanit
upon
exposur
bodi
lice
trench
fever
respons
million
infect
world
war
fever
either
abrupt
indol
onset
maculopapular
rash
conjunct
headach
myalgia
often
affect
leg
splenomegali
describ
urban
b
quintana
infect
occur
often
among
homeless
distinct
clinic
pictur
fever
common
manifest
endocard
occur
mani
bartonella
hensela
global
endem
domest
cat
major
reservoir
major
arthropod
vector
b
hensela
cat
flea
respons
cattocat
transmiss
human
infect
call
cat
scratch
diseas
assum
involv
inocul
bartonellainfect
flea
fece
skin
cat
scratch
b
hensela
caus
primarili
adenopathi
neurolog
symptom
b
bacilliformi
caus
condit
two
phase
acut
phase
fever
anemia
transient
immunosuppress
follow
nodular
dermal
erupt
recent
appreci
ongo
system
featur
erupt
phase
arthralgia
adenopathi
anorexia
diagnosi
bartonellaassoci
diseas
achiev
direct
examin
clinic
materi
bacteriolog
cultur
method
serolog
immunocytochem
studi
pcrbase
assay
combin
method
bartonella
infect
present
differ
immunocompromis
host
addit
higher
preval
bartonella
infect
hiv
patient
b
quintana
b
hensela
induc
neovascular
prolifer
might
involv
skin
lymph
node
varieti
intern
organ
includ
liver
spleen
bone
brain
lung
bowel
etc
neovascular
lesion
known
bacillari
angiomatosispeliosi
babp
initi
describ
hivinfect
patient
advanc
diseas
later
describ
immunocompromis
host
secondari
immunosuppress
treatment
solid
organ
transplant
hematolog
malign
cutan
ba
lesion
vari
present
subcutan
dermal
nodul
singl
multipl
papul
flesh
color
red
purpl
lesion
may
ulcer
bleed
chang
number
size
millimet
centimet
hundr
involv
mucos
surfac
deeper
soft
tissu
similar
variat
seen
viscer
involv
histolog
lesion
consist
lobular
prolifer
small
blood
vessel
neutrophil
predomin
cell
infiltr
term
bacilliari
peliosi
use
describ
bloodfil
cystic
space
mostli
involv
liver
spleen
lymph
node
pathogen
bacteria
isol
vascular
lesion
pathogen
associ
cutan
lesion
b
hensela
associ
viscer
bp
base
hiv
literatur
reason
expect
unusu
present
bartonella
infect
especi
pidd
involv
cell
dysfunct
bartonella
infect
describ
caus
hepat
singl
defici
patient
addit
sinc
case
granulomat
diseas
due
bartonella
infect
describ
consid
differenti
diagnosi
pidd
granulomat
inflamm
borrelia
spp
genu
borrelia
belong
spirochaetacea
famili
includ
b
burgdorferi
caus
lyme
diseas
speci
caus
relaps
fever
latter
divid
tickborn
speci
louseborn
speci
louseborn
relaps
fever
lbrf
caus
borrelia
recurrenti
spread
human
bodi
lous
diseas
epidem
earli
twentieth
centuri
estim
die
lbrf
world
war
ii
sanit
improv
lbrf
found
horn
africa
among
homeless
peopl
europ
recent
case
lbrf
refuge
migrant
describ
tickborn
relaps
fever
tbrf
caus
group
pathogen
maintain
surviv
softtick
orinthodoro
genu
tbrf
borrelia
speci
depend
one
specif
speci
softbodi
tick
except
australia
antarctica
tbrf
speci
found
contin
anim
reservoir
includ
small
anim
rodent
sinc
spirochet
persist
tick
salivari
gland
diseas
transmiss
occur
human
intrud
tick
environ
tick
bite
painless
histori
tick
bite
often
miss
therefor
histori
potenti
exposur
valuabl
major
clinic
symptom
relaps
fever
median
incub
period
day
patient
present
febril
episod
last
day
follow
afebril
period
day
patient
tbrf
febril
relaps
lbrf
usual
associ
one
relaps
symptom
includ
myalgia
arthralgia
headach
vomit
physic
find
includ
lymphadenopathi
splenomegali
rash
occur
third
patient
rang
neurolog
complic
well
system
inflammatori
respons
syndrom
also
describ
diagnosi
base
identifi
spirochet
blood
smear
sensit
blood
smear
higher
febril
period
neg
blood
smear
exclud
rf
lbrf
spirochet
load
low
specif
stain
help
diagnost
method
includ
serolog
test
pcr
mous
inocul
doxycyclin
tetracyclin
penicillin
prefer
treatment
patient
treat
day
doxycyclin
jarischherxheim
reaction
high
fever
leukopenia
occur
half
patient
follow
first
antibiot
dose
develop
sever
reaction
hypotens
respiratori
distress
death
without
treatment
tbrf
carri
mortal
rate
even
higher
mortal
rate
untreat
lbrf
two
case
meningoenceph
borrelia
miyamotoi
heavili
treat
immunocompromis
patient
describ
lyme
borreliosi
common
vectorborn
diseas
northern
hemispher
caus
group
least
genospeci
lyme
diseas
multisystem
ill
affect
skin
joint
nervou
system
heart
human
infect
caus
mainli
three
speci
b
burgdorferi
common
caus
north
america
also
found
europ
borrelia
afzelii
borrelia
garinii
caus
diseas
europ
asia
emerg
infect
midwestern
usa
borrelia
mayonii
caus
condit
similar
lyme
diseas
tick
speci
carri
borrelia
speci
vector
borrelia
speci
ixodid
tick
speci
includ
deer
tick
scapulari
northeast
midwest
usa
ixod
pacificu
west
sheep
tick
ixod
ricinu
europ
taiga
tick
ixod
persulcatu
asia
ixodid
tick
demonstr
complex
vector
ecolog
prefer
differ
host
differ
geograph
region
differ
stage
develop
differ
speci
includ
deer
rodent
bird
reptil
describ
infect
rate
also
show
season
variat
highest
rate
lyme
diseas
follow
sever
stage
start
local
diseas
site
inocul
follow
dissemin
stage
later
persist
infect
howev
individu
patient
show
highli
variabl
diseas
progress
differ
pattern
organ
involv
diseas
sever
erythema
migran
em
often
seen
site
tick
bite
day
incub
region
lymphadenopathi
seen
secondari
skin
lesion
repres
hematogen
dissemin
stage
constitut
symptom
gener
fatigu
fever
headach
migratori
musculoskelet
pain
conjunct
cardiac
involv
occur
total
untreat
patient
develop
frank
neurolog
manifest
mening
enceph
variabl
form
neuriti
fluctuat
symptom
persist
occur
untreat
inadequ
patient
antibiot
refractori
arthriti
well
describ
howev
even
without
treatment
intermitt
persist
attack
usual
resolv
complet
within
sever
year
coinfect
phagocytophilum
b
microti
caus
diagnost
confus
diagnosi
lyme
diseas
establish
base
clinic
symptom
histori
potenti
exposur
serolog
studi
although
posit
cultur
confirm
diagnosi
usual
obtain
earli
em
lesion
pcr
test
superior
cultur
perform
joint
fluid
sampl
cdc
recommend
diagnosi
lyme
diseas
base
serolog
might
imposs
pidd
patient
abnorm
humor
respons
cdc
guidelin
requir
elisa
compar
test
posit
western
blot
band
kd
igm
band
igg
kd
lyme
manifest
treat
oral
antibiot
patient
neurolog
abnorm
patient
lyme
arthriti
requir
intraven
therapi
doxycyclin
treatment
choic
earli
dissemin
diseas
amoxicillin
secondlin
choic
jarischherxheimerlik
reaction
appear
first
h
patient
patient
clear
neurolog
symptom
week
iv
ceftriaxon
commonli
use
therapi
case
neuroborreliosi
hiv
describ
good
respons
treatment
descript
lyme
diseas
pidd
patient
lack
zoonos
infecti
diseas
pass
anim
human
span
spectrum
pathogen
includ
virus
bacteria
fungi
parasit
zoonos
common
rang
mild
certain
form
tinea
lifethreaten
infect
rabi
zoonos
vectorborn
cover
section
risk
mitig
strategi
zoonos
includ
patient
educ
proactiv
advic
risk
scenario
avoid
infect
anim
sever
zoonos
associ
contact
mammal
rodent
domest
farm
anim
direct
contact
contact
fece
instanc
hantaviru
infect
often
associ
exposur
mous
drop
stay
cabin
western
usa
occup
exposur
occur
buffalopox
parapoxviru
caus
orf
infect
direct
contact
buffalo
goatssheep
respect
gener
case
pidd
zoonot
infect
acquir
mammal
howev
special
consider
instanc
lymphocyt
choriomening
viru
acquir
exposur
hous
mice
primarili
hamster
less
common
sourc
infect
domest
wild
mice
carri
infect
without
exhibit
symptom
although
infect
rare
sever
case
patient
nk
cell
dysfunct
case
case
solid
organ
transplant
recipi
therefor
patient
sever
tnk
defect
consider
given
whether
small
rodent
appropri
household
pet
tularemia
diseas
anim
human
caus
bacterium
francisella
tularensi
rabbit
hare
rodent
main
reservoir
human
becom
infect
direct
contact
ingest
contamin
water
inhal
organ
tick
deer
fli
also
transmit
diseas
bite
fever
univers
featur
depend
mode
transmiss
patient
cgd
complex
cours
suggest
myeloid
defect
risk
sever
diseas
rabi
almost
univers
fatal
infect
caus
contact
oral
secret
infect
mammal
typic
raccoon
bat
fox
suggest
pidd
immun
compromis
modifi
prognosi
individu
highrisk
exposur
work
wildlif
travel
endem
area
preexposur
prophylaxi
given
vaccin
exposur
occur
rabiesspecif
immunoglobulin
provid
well
vaccin
howev
humor
immunodefici
respond
typic
preexposur
vaccin
need
counsel
addit
risk
without
vaccin
tabl
sever
bacteri
viral
zoonos
summar
typic
endem
area
somewhat
limit
diagnost
abil
report
well
typic
clinic
scenario
known
case
immunodefici
approach
diagnosi
therapi
nipah
viru
caus
rang
infecti
phenotyp
rang
asymptomat
infect
acut
respiratori
distress
enceph
nipah
viru
identifi
pig
farm
malaysia
lead
identif
human
case
includ
human
death
cull
one
million
pig
natur
host
fruit
bat
pteropodida
pteropu
symptom
infect
malaysian
outbreak
primarili
encephalit
human
later
outbreak
caus
respiratori
ill
increas
likelihood
humantohuman
transmiss
fever
headach
cough
abdomin
pain
nausea
vomit
weak
problem
swallow
blur
vision
common
seizur
seen
coma
relaps
enceph
describ
increas
infect
due
nipah
viru
thought
due
increas
overlap
bat
habitat
pig
sti
malaysia
outbreak
thu
far
india
bangladesh
malaysia
diagnosi
nipah
viru
reli
pcr
fluid
sampl
serolog
convalesc
sampl
immunofluoresc
tissu
infect
immun
compromis
patient
report
therapi
larg
support
although
preliminari
report
ribavirin
use
encourag
vaccin
develop
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
two
zoonot
coronavirus
sar
pandem
result
report
case
countri
sar
case
report
pandem
except
isol
case
link
laboratori
accid
patient
usual
present
fever
respiratori
symptom
occasion
diarrhea
vomit
sar
patient
requir
mechan
ventil
case
fatal
rate
mer
first
note
saudi
arabia
countri
around
arabian
peninsula
endem
merscov
patient
usual
present
fever
cough
chill
sore
throat
myalgia
arthralgia
rapidli
progress
pneumonia
patient
requir
intens
care
onethird
patient
present
diarrhea
vomit
acut
renal
impair
strike
featur
mer
risk
factor
poor
outcom
includ
diabet
hypertens
renal
lung
diseas
case
export
least
countri
travel
occasion
caus
cluster
secondari
outbreak
one
exampl
merscov
outbreak
involv
patient
south
korea
median
incub
period
estim
day
rang
day
end
confirm
mer
mortal
rate
bat
natur
reservoir
sarscov
merscov
sarscov
cross
speci
barrier
palm
civet
anim
live
anim
market
china
infect
human
merscov
ancestr
viru
cross
speci
barrier
dromedari
camel
abund
circul
merscov
camel
result
continu
zoonot
transmiss
viru
human
sarscov
found
circul
intermedi
reservoir
explain
sar
oneoff
outbreak
mer
continu
zoonot
diseas
aerosolgener
procedur
intub
associ
increas
viral
transmiss
cov
result
nosocomi
outbreak
superspread
respons
larg
prolong
outbreak
diagnosi
sar
mer
includ
serolog
test
pcr
assay
quantifi
viral
load
function
genet
polymorph
lead
low
serum
mannos
bind
lectin
mbl
associ
suscept
sever
sar
southern
northern
chines
mbl
shown
bind
sarscov
inhibit
infect
suggest
role
firstlin
defens
sarscov
although
patient
primari
immunodefici
infect
sarscov
merscov
identifi
like
due
limit
number
infect
patient
cell
defect
type
interferon
pathway
defect
could
suffer
sever
diseas
cours
virusbas
hostbas
treatment
strategi
larg
experiment
uncertain
benefit
ribavirin
type
interferon
small
molecul
monoclon
antibodi
block
cov
entri
explor
passiv
immunotherapi
multipl
candid
vaccin
test
variou
anim
model
convalesc
plasma
immunotherapi
consid
clinic
trial
lack
mer
sar
systemat
review
conclud
convalesc
serum
may
reduc
mortal
appear
safe
filovirida
famili
contain
three
known
genera
ebolavirus
marburgvirus
cuevaviru
ebolaviru
marburgviru
caus
hemorrhag
fever
syndrom
primat
human
high
fatal
rate
cuevaviru
infect
bat
ebolaviru
genu
contain
five
speci
two
speci
zair
ebolaviru
sudan
ebolaviru
respons
major
case
human
diseas
marburgvirus
contain
two
speci
marburg
viru
ravn
viru
filovirus
capabl
replic
number
cell
type
except
neuron
lymphocyt
upon
entri
bodi
host
via
break
skin
parenter
mucos
surfac
filovirus
employ
varieti
mechan
evad
activ
immun
system
incub
period
interv
infect
onset
symptom
vari
day
symptom
begin
abruptli
high
fever
sever
headach
malais
myalgia
diarrhea
nausea
vomit
rash
occur
day
onset
symptom
hemorrhag
manifest
occur
day
fatal
case
usual
form
activ
bleed
outbreak
set
symptom
unmistak
confus
malaria
occur
earli
diseas
sporad
case
sinc
origin
descript
respect
marburg
ebola
number
sporad
case
sever
major
outbreak
largest
marburg
viru
outbreak
occur
angola
fatal
rate
largest
ebola
epidem
happen
west
africa
sierra
leon
guinea
liberia
claim
live
fatal
rate
although
definit
proven
case
ebola
bat
believ
natur
anim
reservoir
virus
virus
transmit
via
contact
blood
bodi
fluid
infect
host
notabl
certain
bodi
fluid
harbor
viru
week
month
resolut
diseas
given
recent
outbreak
west
africa
renew
interest
understand
pathogenesi
filoviru
infect
possibl
therapi
literatur
regard
pathogenesi
diseas
may
alter
patient
pidd
lack
howev
assumpt
absenc
intact
cellular
andor
humor
immun
respons
patient
pidd
may
increas
risk
mortal
set
mortal
alreadi
high
virus
induc
apoptosi
lymphocyt
macrophag
therefor
profound
secondari
immun
compromis
filovirus
detect
multipl
bodi
fluid
via
pcr
although
practic
decad
studi
guinea
fail
show
decreas
mortal
among
patient
receiv
convalesc
plasma
previous
infect
donor
number
addit
compound
eg
tkmebola
biolog
zmapp
shown
offer
protect
anim
model
ebola
date
control
appropri
power
clinic
trial
address
efficaci
human
final
number
vaccin
ebola
undergo
clinic
studi
includ
four
phase
iii
trial
importantli
late
rvsvzebov
vaccin
shown
display
high
efficaci
protect
immun
adult
guinea
ebola
outbreak
data
also
suggest
vaccin
may
even
offer
bherd
immunityto
unimmun
person
proxim
recipi
vaccin
hepat
e
viru
singlestrand
rna
viru
hepevirida
famili
import
zoonot
diseas
asia
africa
fecalor
spread
usual
rout
transmiss
handl
pig
boar
meat
risk
factor
pig
liver
sold
groceri
store
japan
usa
infect
swine
repres
major
reservoir
although
antibodi
viru
found
mani
speci
incub
period
week
month
viremia
disappear
onset
symptom
mortal
rate
reach
pregnanc
acut
hepat
usual
resolv
lead
liver
failur
sever
case
patient
hepat
e
posttranspl
sever
cours
case
immun
compromis
patient
cours
becom
chronic
case
cirrhosi
develop
diagnosi
serolog
pcr
treatment
support
prevent
modal
infect
transmit
human
conceptu
differ
infect
prevent
vectorborn
infect
hand
hygien
extrem
import
avoid
clearli
infect
peopl
help
recognit
infect
fecalor
transmiss
import
water
puriti
critic
patient
pidd
contrast
infect
transmit
aerosol
requir
prevent
strategi
relat
droplet
precaut
outbreak
scenario
risk
patient
high
specif
chemoprophylaxi
may
consid
influenza
virus
type
b
caus
annual
epidem
influenza
type
c
caus
sporad
mild
influenzalik
ill
patient
present
sudden
onset
fever
chill
myalgia
follow
sore
throat
cough
less
common
featur
includ
diarrhea
acut
myositi
encephalopathi
coinfect
bacteria
pneumococci
result
sever
diseas
influenza
pandem
occur
yearli
around
world
influenza
virus
infect
global
popul
result
death
annual
virus
circul
asia
continu
seed
temper
zone
begin
oceania
north
america
europ
later
seed
south
america
diagnosi
influenza
includ
direct
indirect
immunofluoresc
antibodi
stain
antigen
nasopharyng
aspir
pcr
patient
compound
heterozyg
null
mutat
gene
encod
transcript
factor
amplifi
report
lifethreaten
influenza
primari
infect
fatal
influenzaassoci
encephalopathi
chines
japanes
children
report
associ
genet
variant
thermolabil
carnitin
palmitoyltransferas
ii
patient
scid
prolong
viral
shed
sever
pandem
influenza
viru
infect
associ
subclass
defici
addit
influenza
infect
sever
pidd
patient
underli
lung
diseas
bronchiectasi
antibiot
coverag
chronic
colon
bacteria
pseudomona
set
may
help
inactiv
season
influenza
vaccin
given
pidd
patient
even
humor
defici
cell
respons
influenza
could
normal
offer
protect
immun
sever
influenza
antivir
drug
includ
neuraminidas
inhibitor
oseltamivir
zanamir
adamantan
amantadin
rimantadin
resist
adamantan
widespread
measl
singlestrand
negativesens
envelop
nonseg
rna
viru
genu
morbilliviru
measl
highli
communic
transmit
droplet
less
commonli
airborn
spread
patient
present
fever
cough
coryza
conjunct
rash
koplik
spot
complic
includ
pneumonia
acut
enceph
subacut
scleros
panenceph
sspe
diagnosi
measl
includ
serolog
test
viru
isol
pcr
outbreak
clinic
featur
may
suffici
diagnosi
measl
vaccin
caus
sever
measl
children
receptor
defici
demonstr
import
type
interferon
pathway
control
measl
immun
compromis
nearli
type
associ
sever
diseas
higher
mortal
cell
defici
state
strongli
associ
develop
giant
cell
pneumonia
inclus
bodi
enceph
fear
complic
measl
sspe
slow
enceph
due
persist
replic
defect
measl
viru
cn
frequent
seen
young
infant
infect
measl
year
later
sspe
becom
evid
case
report
support
immun
compromis
increas
risk
sspe
treatment
sspe
ribavirin
shown
improv
prognosi
gener
sspe
grave
patient
cgd
defect
memori
b
cell
compart
result
lower
measlespecif
antibodi
level
antibodysecret
cell
number
sever
diseas
report
pidd
patient
may
harbor
viru
latent
longer
usual
lead
complic
time
transplant
specif
antivir
therapi
lack
ribavirin
given
sever
ill
immunocompromis
children
measl
postexposur
prophylaxi
intraven
immunoglobulin
ivig
recommend
sever
immunocompromis
patient
without
evid
measl
immun
would
like
includ
patient
scid
hypogammaglobulinemia
yet
regular
ivig
measl
vaccin
given
twodos
regimen
brought
incid
enorm
worldwid
plan
erad
global
enterovirus
ev
among
common
virus
infect
human
worldwid
ev
small
nonenvelop
singlestrand
rna
virus
picornavirida
famili
human
ev
categor
seven
speci
includ
hundr
serotyp
poliovirus
pv
coxsacki
virus
b
cva
b
echovirus
human
rhinovirus
hrv
speci
mani
import
serotyp
known
infect
human
hrv
tabl
nonpolio
enterovirus
npev
worldwid
distribut
infant
young
children
higher
incid
infect
sever
cours
ill
adult
mode
transmiss
mainli
fecalor
respiratori
rout
infect
occur
around
year
tropic
subtrop
region
temper
climat
peak
incid
infect
summer
fall
month
npev
associ
divers
clinic
manifest
rang
mild
febril
ill
sever
potenti
fatal
condit
case
asymptomat
mild
symptom
includ
fever
without
rash
symptom
hand
foot
mouth
diseas
herpangina
acut
hemorrhag
conjunct
upper
respiratori
infect
gastroenter
sever
symptom
occur
infant
young
children
acut
flaccid
paralysi
neonat
enterovir
sepsi
myocarditispericard
hepat
pancreat
pneumonia
atyp
hemolyt
urem
syndrom
sever
manifest
seen
immunocompet
peopl
chronic
infect
seen
immunocompromis
patient
viru
may
produc
one
aforement
manifest
howev
serotyp
often
associ
particular
featur
tabl
definit
diagnosi
npev
infect
reli
pcr
viru
isol
cerebrospin
fluid
blood
stool
urin
throat
swab
treatment
npev
mainli
support
sinc
infect
selflimit
high
dose
intraven
immunoglobulin
ivig
recommend
patient
sever
symptom
efficaci
new
antivir
drug
pleconaril
vapendavir
pocapavir
still
investig
vaccin
licens
yet
npev
howev
phase
clinic
trial
inactiv
monoval
vaccin
manufactur
china
show
high
efficaci
infant
young
children
patient
varieti
pidd
unusu
suscept
ev
suscept
group
patient
primari
antibodi
defici
xla
cvid
hyperigm
syndrom
higm
well
scid
major
histocompat
class
ii
defici
sever
form
infect
describ
patient
xla
due
profound
defici
immunoglobulin
essenti
viral
neutral
infect
affect
patient
usual
present
indol
relentlessli
progress
nonnecrot
meningoenceph
regress
cognit
skill
flaccid
quadriplegia
deaf
describ
report
nonneurolog
present
xla
includ
septicemia
dermatomyositislik
diseas
hepat
andor
arthriti
incid
npev
meningoenceph
larg
registri
xla
case
unpublish
data
kuwait
nation
pidd
registri
includ
pidd
patient
show
nine
patient
document
npev
infect
two
die
infect
two
death
seen
scid
patient
person
commun
prof
wale
alherz
md
addit
npev
meningoenceph
andor
septicemia
report
case
either
primari
b
cell
defici
b
cell
linker
blink
protein
defici
acquir
b
cell
defici
follow
administr
rituximab
report
better
outcom
attribut
earli
administr
high
dose
ivig
npev
viremia
npev
infect
pidd
diseas
remain
major
threat
patient
also
possibl
prolong
viral
excret
emerg
resist
strain
run
risk
spread
infect
surround
commun
oral
polio
vaccin
opv
consist
mixtur
three
live
attenu
polioviru
serotyp
opv
induc
product
neutral
antibodi
three
serotyp
addit
local
intestin
immun
respons
opv
result
vaccineassoci
paralysi
vap
secondari
revers
vaccin
strain
neurovirul
wildtyp
strain
exampl
event
demonstr
outbreak
dominican
republ
haiti
believ
driven
least
part
undervaccin
popul
allow
spread
revert
vaccin
strain
although
rare
patient
pidd
higher
risk
develop
vap
report
shown
pidd
patient
antibodi
defici
prolong
viral
replic
persist
year
therefor
theoret
increas
risk
spontan
revers
within
immunodefici
host
case
vap
shown
patient
antibodi
defici
combin
immunodefici
syndrom
therefor
opv
contraind
patient
pidd
contraind
extend
household
contact
beyond
obviou
risk
pidd
patient
prolong
viru
shed
also
increas
risk
spread
vaccinederiv
paralyt
strain
gener
popul
bacteri
infect
mold
human
behavior
alter
societi
human
histori
today
larg
ignor
due
antibiot
suscept
continu
caus
miseri
diseas
around
world
three
infect
highlight
addit
commonli
encount
infect
list
tabl
pertussi
respiratori
infect
caus
bordetella
pertussi
begin
incub
period
minor
upper
respiratori
infect
progress
cough
initi
intermitt
evolv
paroxysm
cough
spell
usual
follow
vomit
infant
young
children
last
week
mani
complic
syncop
weight
loss
rib
fractur
pneumonia
infant
month
sever
affect
develop
pneumonia
pulmonari
hypertens
hypoxia
subdur
bleed
seizur
death
occur
especi
young
infant
adult
typic
prolong
cough
fewer
complic
transmit
via
aerosol
droplet
close
contact
peopl
contagi
catarrh
stage
first
half
paroxysm
phase
total
week
introduct
wholecel
pertussi
vaccin
dpt
usa
reduc
incid
diseas
case
around
case
per
year
resurg
associ
substitut
wholecel
vaccin
acellular
pertussi
vaccin
dtap
new
strategi
booster
acellular
pertussi
adolesc
adult
tdap
use
tdap
pregnanc
seem
effect
partial
reduc
incid
diseas
howev
pertussi
case
usa
remain
higher
lack
persist
antibodi
adult
popul
mean
adult
repres
reservoir
diseas
also
provid
suffici
titer
immunoglobulin
product
prepar
adult
plasma
pool
rel
recent
requir
countri
vaccin
adult
everi
year
maintain
immun
time
improv
titer
immunoglobulin
product
cultur
specimen
obtain
nasopharyng
swab
gold
standard
laboratori
diagnosi
due
specif
polymeras
chain
reaction
pcr
gain
promin
due
higher
sensit
speed
result
serodiagnosi
use
late
stage
diseas
filament
hemagglutinin
fha
pertussi
toxin
pt
antibodi
detect
peak
measur
pidd
patient
regular
ivig
although
pt
antibodi
protect
level
trough
measur
sever
pertussi
case
report
pidd
patient
sever
diseas
seen
malign
antimicrobi
azithromycin
erythromycin
clarithromycin
given
catarrh
stage
may
amelior
diseas
shorten
contagi
period
avoid
case
pertussi
also
worth
emphas
import
good
vaccin
coverag
rate
among
whole
popul
especi
among
healthcar
worker
famili
member
patient
pidd
neisseria
meningitidi
onset
neisseri
mening
associ
sore
throat
headach
drowsi
fever
irrit
neck
stiff
purpur
lesion
characterist
pathogen
also
present
sepsi
mortal
rate
oppos
mortal
meningit
present
bacterium
also
caus
chronic
condit
refer
chronic
meningococcemia
condit
character
intermitt
fever
last
week
month
nonpurpur
rash
common
may
evolv
purpura
arthriti
similar
seen
gonococcu
common
meningococc
diseas
primarili
affect
children
year
age
n
meningitidi
global
pathogen
serogroup
major
invas
meningococc
infect
caus
organ
b
c
x
w
serogroup
annual
number
invas
diseas
case
worldwid
estim
least
million
death
relat
invas
meningococc
diseas
serogroup
b
c
respons
infect
europ
serogroup
histor
major
organ
africa
mass
vaccin
led
improv
emerg
group
x
diseas
worrisom
hajj
middl
east
seen
epidem
vaccin
requir
hajj
travel
b
c
serogroup
common
america
n
meningitidi
case
occur
rate
case
per
peopl
throughout
world
across
sahel
africa
china
epidem
lead
case
rate
per
bacterium
natur
human
commens
carriag
rate
diagnosi
clinic
examin
epidem
gram
stain
cultur
complementdefici
individu
increas
risk
neisseri
diseas
necessarili
increas
mortal
hiv
associ
increas
diseas
suggest
cell
also
import
defens
thirdgener
cephalosporin
typic
use
treatment
penicillin
ampicillin
aztreonam
chloramphenicol
altern
great
interindividu
variabl
develop
tb
diseas
roughli
infect
individu
develop
clinic
diseas
within
year
infect
mostli
childhood
becam
latent
infect
without
clinic
diseas
remain
develop
pulmonari
tb
later
life
either
reactiv
latent
infect
reinfect
molecular
epidemiolog
studi
high
burden
area
suggest
diseas
result
recent
transmiss
reactiv
latent
tb
particularli
peopl
live
hiv
acquir
inherit
host
factor
may
least
partial
account
variabl
diseas
cours
result
increas
suscept
mycobacteria
infect
pidd
associ
tb
ntm
infect
includ
cell
defici
defici
cgd
anhidrot
ectoderm
dysplasia
immunodefici
xlink
xl
recess
ligand
defici
autosom
recess
ar
defici
ar
defici
ar
defici
addit
group
disord
strong
suscept
ntm
name
mendelian
suscept
mycobacteri
diseas
msmd
recogn
sinc
rare
inborn
error
signal
pathway
present
isol
predisposit
infect
caus
weakli
virul
mycobacteria
bcg
vaccin
environment
ntm
otherwis
healthi
patient
genet
defect
involv
impair
product
interferon
ar
ar
autosom
domin
ad
ar
xl
recess
nemo
respons
interferon
ad
ad
cgd
acquir
form
exit
adult
ntm
infect
thailand
taiwan
found
hightit
antiinterferongamma
antibodi
individu
southeast
asia
found
patient
suspect
pulmonari
tb
acidfast
bacilli
afb
smear
microscopi
cultur
perform
three
sputum
sampl
pcr
mtb
perform
use
rapid
test
facilit
earli
diagnosi
recent
recommend
use
recommend
rapid
test
detect
tb
without
rifampicin
resist
xpert
mtbrif
assay
cepheid
sunnyval
ca
recommend
xpert
test
suspect
drugresist
tb
hiv
howev
cultur
still
mainstay
replac
xpert
test
tb
skin
test
mantoux
test
use
purifi
protein
deriv
inject
skin
advantag
use
largescal
screen
cost
effect
skin
test
sever
disadvantag
use
diagnost
test
read
indur
requir
train
immunodefici
alter
magnitud
indur
immunosuppress
patient
hiv
organ
transplant
consid
posit
indur
mm
immunodefici
may
complet
ablat
respons
caus
falseneg
test
malnutrit
concurr
infect
recent
live
viral
vaccin
administr
renal
failur
malign
medic
stress
elderli
young
infant
recent
infect
mtb
convers
result
may
fals
posit
bcg
administ
interferon
gamma
releas
assay
use
set
skin
test
would
done
consid
superior
set
patient
bcg
vaccin
case
skin
test
sown
high
falseneg
rate
gener
tb
treatment
patient
impair
immun
respons
includ
pidd
hiv
infect
immunosuppress
therapi
base
standard
regimen
consist
intens
phase
isoniazid
rifampin
pyrazinamid
ethambutol
follow
month
isoniazid
rifampin
decis
regard
treatment
durat
individu
take
account
diseas
sever
organ
involv
respons
treatment
signific
pharmacolog
interact
occur
rifampinbas
mtb
regimen
immunosuppress
drug
calcineurin
inhibitor
rapamycin
requir
strict
monitor
drug
plasma
concentr
therapi
ntm
complex
highli
variabl
drug
resist
pattern
need
biolog
augment
effect
clear
organ
aspergillu
fumigatu
see
cryptococcu
gattii
histoplasma
capsulatum
coccidioid
immiti
c
posadasii
blastomyc
dermatitidi
paracoccidioid
brasiliensi
emmonsia
pasteuriana
penicillium
talaromyc
marneffei
environment
fungi
endem
certain
part
world
tabl
except
penicillium
marneffei
emmonsia
pasteuriana
caus
diseas
profoundli
immun
compromis
individu
fungi
caus
infect
healthi
individu
rang
mild
selflimit
pulmonari
diseas
infect
requir
antifung
therapi
erad
hand
patient
acquir
defect
cellmedi
immun
infect
hiv
patient
specif
monogen
disord
particularli
involv
signal
pathway
scid
depend
underli
state
immunosuppress
magnitud
environment
exposur
icl
idiopath
lymphocytopenia
aid
acquir
immun
defici
syndrom
signal
transduc
activ
transcript
gata
bind
protein
scid
sever
combin
immunodefici
cvid
common
variabl
immun
defici
pidd
primari
immunodefici
receptor
subunit
beta
gamma
interferon
receptor
defici
high
risk
develop
lifethreaten
dissemin
infect
endem
fungi
follow
environment
exposur
diagnosi
reli
cultur
correspond
fungu
histopatholog
demonstr
fungusspecif
characterist
morpholog
andor
surrog
serolog
fungal
antigen
test
treatment
clinic
diseas
oppos
colon
typic
involv
initi
induct
phase
amphotericin
b
follow
longterm
azol
mainten
therapi
secondari
prophylaxi
prognosi
vari
significantli
depend
fungal
pathogen
underli
pidd
melioidosi
caus
b
pseudomallei
gramneg
bacteria
found
soil
water
tropic
climat
southeast
asia
northern
australia
melioidosi
emerg
potenti
fatal
diseas
mortal
b
pseudomallei
transmit
inhal
ingest
direct
contact
open
skin
contamin
soil
water
anim
sheep
goat
swine
hors
cat
dog
cattl
also
suscept
infect
case
zoonot
transmiss
direct
contact
skin
lesion
infect
anim
meat
milk
describ
b
pseudomallei
infect
endem
northern
australia
southeast
asia
approxim
report
infect
occur
raini
season
case
also
report
south
pacif
africa
india
middl
east
temper
area
infect
extrem
rare
predominantli
import
travel
immigr
incub
period
melioidosi
variabl
day
year
although
common
symptom
develop
week
exposur
melioidosi
present
frequent
adult
year
age
occur
age
one
studi
report
case
occur
children
australia
averag
annual
incid
report
case
per
peopl
incid
indigen
australian
higher
case
per
caseclust
australian
commun
associ
postcyclon
flood
recent
review
suggest
b
pseudomallei
increasingli
preval
america
mortal
rate
infect
healthi
individu
uncommon
case
occur
set
underli
condit
chronic
renal
diseas
diabet
chronic
lung
diseas
alcohol
recent
review
melioidosi
travel
found
case
acquir
thailand
symptom
usual
start
day
rang
day
leav
endem
area
travel
infect
less
often
associ
predispos
risk
factor
diabet
mellitu
common
melioidosi
travel
lower
mortal
infect
autochthon
case
southeast
asia
pneumonia
common
present
adult
usual
high
fever
headach
anorexia
myalgia
b
pseudomallei
infect
may
also
present
local
skin
infect
septicemia
dissemin
infect
local
infect
result
ulcer
nodul
skin
abscess
usual
occur
bacterium
breach
break
skin
patient
renal
diseas
diabet
suscept
sepsi
dissemin
infect
abscess
may
develop
liver
spleen
lung
prostat
children
primari
cutan
melioidosi
commonest
present
bacteremia
less
common
children
adult
brainstem
enceph
report
difficulti
laboratori
diagnosi
melioidosi
may
delay
treatment
affect
diseas
outcom
diagnosi
melioidosi
primarili
isol
organ
identif
b
pseudomallei
difficult
clinic
microbiolog
laboratori
especi
nonendem
area
clinic
suspicion
low
although
variou
serolog
test
develop
gener
unstandard
bin
houseassay
low
sensit
specif
pcr
assay
appli
clinic
environment
specimen
wide
avail
sensit
remain
evalu
case
melioidosi
report
patient
acquir
inherit
immun
defici
melioidosi
present
complaint
sever
patient
cgd
bacterem
melioidosi
recent
report
two
patient
prolong
neutropenia
succumb
despit
appropri
antibiot
like
increas
suscept
situat
innat
adapt
immun
compromis
treatment
intraven
antimicrobi
therapi
day
follow
month
oral
antimicrobi
therapi
intraven
therapi
ceftazidim
meropenem
usual
effect
oral
therapi
may
continu
trimethoprimsulfamethoxazol
doxycyclin
freeliv
amoeba
fla
protozoa
found
worldwid
requir
host
surviv
fla
employ
vector
transmiss
well
adapt
parasit
human
howev
four
generaspeci
caus
human
diseas
naegleria
n
fowleri
acanthamoeba
multipl
speci
balamuthia
b
mandrillari
sappinia
pedata
amoeba
capabl
induc
cn
diseas
human
acanthamoeba
speci
also
caus
variou
extracn
infect
especi
immunocompromis
host
fla
pathogen
human
review
naegleria
divers
group
fla
flagel
protozoan
larg
number
distinct
speci
one
speci
n
fowleri
shown
caus
infect
human
n
fowleri
multistag
life
cycl
amoeboid
trophozoiteinfect
form
well
cyst
form
n
fowleri
found
commonli
warm
freshwat
around
world
includ
lake
river
hot
spring
human
becom
becom
infect
swim
dive
contamin
water
rare
circumst
infect
also
attribut
exposur
contamin
tap
water
sourc
util
religi
cleans
nose
irrig
sinus
thu
tap
water
use
nasal
sinu
irrig
possibl
becom
infect
drink
contamin
water
contact
infect
person
amoeba
found
salt
water
entri
nasal
caviti
amoeba
travel
cribiform
plate
olfactori
bulb
migrat
cerebellum
result
primari
amoeb
meningoenceph
pam
rapidli
fatal
brain
infect
character
destruct
brain
tissu
initi
present
pam
mimic
bacteri
mening
delay
accur
diagnosi
initi
therapi
may
save
patient
overal
n
fowleri
infect
rare
worldwid
case
report
usa
australia
europ
howev
develop
countri
suspect
larg
number
case
go
unreport
infect
report
usa
case
attribut
contamin
recreat
water
infect
follow
nasal
irrig
contamin
tap
water
case
person
infect
follow
use
backyard
slipnslid
util
contamin
tap
water
fatal
rate
associ
n
fowleri
infect
infect
person
usa
surviv
infect
initi
symptom
pam
start
day
infect
includ
headach
fever
nausea
vomit
progress
symptom
includ
stiff
neck
confus
lack
attent
loss
balanc
seizur
hallucin
cardiac
arrhythmia
also
observ
infect
progress
rapidli
initi
onset
caus
death
within
day
exposur
mean
day
sinc
infect
often
progress
rapidli
death
often
insuffici
time
mount
robust
immun
respons
howev
innat
neutrophil
macrophag
complement
system
adapt
b
cell
arm
immun
system
shown
particip
immun
respons
n
fowleri
patient
pam
csf
elev
pressur
often
cloudi
hemorrhag
neutrophilpredomin
pleiocytosi
elev
protein
level
low
glucos
wet
mount
centrifug
csf
show
motil
mononucl
trophozoit
size
addit
trophozoit
identifi
giemsa
wright
stain
csf
smear
combin
enflagel
test
confirm
achiev
via
varieti
timeconsum
method
includ
immunofluoresc
assay
cultur
csf
pcrbase
method
optim
therapi
n
fowleri
pam
still
debat
use
intraven
amphotericin
b
fluconazol
follow
oral
administr
rifampin
result
surviv
child
pam
anoth
child
shown
surviv
follow
intraven
intrathec
amphotericin
b
miconazol
well
oral
rifampin
recent
adolesc
girl
success
treat
combin
azithromycin
rifampin
fluconazol
miltefosin
prevent
critic
highli
fatal
infect
warn
pidd
patient
use
tap
water
nasal
irrig
import
sinc
origin
descript
case
b
mandrillari
infect
describ
worldwidewith
case
occur
south
america
usa
balamuthia
found
soil
acquisit
diseas
associ
agricultur
activ
dirtbik
garden
swim
contamin
water
sourc
b
mandrillari
thought
enter
bodi
host
break
skin
via
inhal
organ
believ
access
cn
hematogen
spread
result
chronic
insidi
often
fatal
granulomat
amoeb
enceph
gae
document
immunocompet
immunocompromis
host
incub
period
exposur
develop
clinic
symptom
well
establish
expert
believ
may
occur
month
year
final
altern
mode
transmiss
via
solid
organ
transplant
also
gain
attent
mani
case
gae
diagnos
postmortem
due
delay
diagnosi
unawar
clinic
entiti
follow
infect
b
mandrillari
two
clinic
pattern
present
describ
first
pattern
patient
initi
develop
skin
lesion
may
resembl
painless
plaqu
may
evolv
subcutan
nodul
rare
ulcer
patient
may
develop
neurolog
manifest
week
month
later
histopatholog
examin
lesion
typic
reveal
granulomat
reaction
reticular
dermi
associ
lymphocyt
plasma
cell
infiltr
well
multinucl
giant
cell
without
distinct
epiderm
chang
skin
lesion
harbor
trophozoit
scarc
often
easili
overlook
resembl
histiocyt
believ
earli
diagnosi
b
mandrillari
infect
present
skin
lesion
may
prevent
subsequ
develop
cn
diseas
also
case
patient
present
skin
lesion
progress
develop
gae
despit
treatment
second
pattern
patient
present
cn
involv
without
previous
recogn
skin
lesion
patient
present
gae
may
initi
display
fever
malais
headach
nausea
vomit
frank
lethargi
later
symptom
evolv
visual
abnorm
cranial
nerv
palsi
seizur
focal
paresi
intracrani
pressur
build
coma
eventu
death
tonsilar
uncal
herniat
ensu
within
week
upon
infect
b
mandrillari
brain
endotheli
cell
produc
proinflammatori
cytokin
therebi
initi
inflammatori
respons
moreov
amoeb
trophozoit
infiltr
blood
vessel
wall
degrad
enzym
vessel
wall
infiltr
host
inflammatori
respons
result
tissu
necrosi
infarct
cerebr
hemispher
cerebellum
brainstem
mous
model
b
mandrillari
infect
cell
shown
protect
suggest
patient
lower
number
dysfunct
cell
may
suscept
diseas
amoeba
howev
b
mandrillari
infect
describ
varieti
human
host
rang
young
healthi
presum
immunocompet
elderli
hiv
chronic
corticosteroid
exposur
posttranspl
immunosuppress
even
patient
cvid
research
necessari
fulli
delin
suscept
pidd
patient
patient
develop
characterist
skin
lesion
recognit
test
treatment
b
mandrillari
may
prevent
subsequ
gae
obtain
tissu
look
granuloma
trophozoit
quit
help
skin
biopsi
stain
via
immunofluoresc
immunoperoxidas
techniqu
identifi
b
mandrillari
addit
pcr
techniqu
identifi
mitochondri
ribosom
rna
b
mandrillari
also
avail
cdc
patient
diagnosi
confirm
via
skin
biopsi
wide
resect
medic
treatment
appear
prevent
develop
cn
diseas
least
proport
patient
patient
present
cn
involv
lumbar
punctur
reveal
csf
lymphocyt
pleiocytosi
lowtonorm
glucos
mildli
significantli
elev
protein
level
trophozoit
typic
found
csf
pcr
analysi
may
perform
ct
mr
imag
may
show
multipl
nodul
ring
enhanc
nodul
may
also
contain
focal
area
hemorrhag
biopsi
brain
tissu
typic
reveal
granuloma
foami
macrophag
multinucl
giant
cell
surround
lymphocyt
infiltr
addit
area
necrosi
fill
neutrophil
multinucl
giant
cell
lymphocyt
balamuthia
trophozoit
cyst
interspers
macrophag
skin
biopsi
immunofluoresc
immunoperoxidas
stain
may
aid
diagnosi
perform
unfortun
optim
medic
manag
cn
diseas
unknown
usa
patient
success
treat
combin
fluconazol
flucytosin
pentamidin
macrolid
antibiot
either
clarithromycin
azithromycin
one
follow
agent
liposom
amphotericin
b
miltefosin
sulfadiazin
thoridazin
other
peru
treat
success
fluconazol
itraconazol
albendazol
miltefosin
base
case
report
expert
recommend
treatment
combin
medic
along
partial
complet
resect
nodul
prolong
period
time
prevent
deterior
death
acanthamoeba
spp
genu
acanthamoeba
contain
least
morpholog
distinct
speci
live
divers
array
habitat
includ
soil
salt
brackish
fresh
water
acanthamoeba
spp
also
found
humidifi
heat
cool
unit
compon
jacuzzi
hot
water
tank
bathroom
drain
eye
wash
station
dentistri
irrig
system
acanthamoeba
spp
isol
reptil
bird
nonhuman
mammal
suggest
broad
distribut
environ
acanthamoeba
trophozoit
feed
bacteria
also
recent
shown
harbor
number
bacteria
includ
legionella
burkholderia
spp
e
coli
listeria
monocytogen
vibrio
cholera
mycobacteria
spp
chlamydophila
other
least
one
viru
mimiviru
endosymbiont
acanthamoeba
infect
human
present
varieti
way
primari
import
cn
infect
like
b
mandrillari
acanthamoeba
spp
induc
gae
describ
high
predilect
gae
hivaid
patient
chemotherapi
receiv
broad
spectrum
antibiot
acanthamoeba
rare
found
csf
case
report
indic
isol
amoeba
cultur
csf
bacter
agar
plate
similar
gae
seen
b
mandrillari
cn
histopatholog
may
reveal
edema
multipl
area
necrosi
hemorrhag
occasion
find
angiti
blood
vessel
cuf
inflammatori
cell
well
occasion
trophozoit
cyst
cn
diseas
treatment
standard
sever
patient
success
treat
pentamidin
fluconazol
flucytosin
sulfadiazin
well
miltefosin
acanthamoeba
rare
caus
cutan
infect
lesion
like
gae
also
predominantli
seen
immunocompromis
host
lesion
start
nodul
papul
lower
extrem
develop
necrot
ulcer
histopatholog
examin
may
reveal
granulomat
dermal
lesion
immunocompet
host
histiocyt
well
neutrophil
plasmacyt
trophozoit
typic
visibl
optim
manag
cutan
diseas
known
typic
involv
combin
therapi
topic
eg
chlorhexidin
glucon
ketoconazol
system
miltefosin
sulfadiazin
flucytosin
liposom
amphotericin
b
azol
antifung
etc
drug
addit
nasopharyng
sinu
infect
seen
peopl
sever
compromis
immun
patient
typic
present
purul
nasal
discharg
examin
may
reveal
eros
nasal
septum
nasopharyng
diseas
present
concomitantli
cutan
diseas
treatment
nasopharyng
sinu
diseas
difficult
involv
surgic
debrid
combin
system
drug
dissemin
diseas
also
seen
immunocompromis
host
typic
involv
concomit
pulmonari
cutan
diseas
presenc
absenc
cn
infect
kerat
readili
occur
immunocompet
hostswith
major
risk
factor
contact
len
wear
without
proper
adher
recommend
cleans
protocol
infect
less
commonli
present
result
direct
inocul
trauma
one
common
reason
contact
len
wearer
acquir
diseas
due
use
nonsteril
tap
water
prepar
contact
len
salin
solut
although
contamin
solut
manufactur
also
identifi
patient
pain
photophobia
physic
exam
reveal
conjunctiv
inject
epitheli
abnorm
includ
pseudodendrit
lesion
stromal
infiltr
proper
diagnosi
made
stain
corneal
scrape
calcofluor
wrightgiemsa
stain
examin
confoc
microscopi
cultur
pcr
analysi
prompt
therapi
combin
polyhexamethylen
biguanid
biguanidechlorhexidin
propamidin
hexamidin
indic
misdiagnosi
delay
therapi
common
sever
case
may
also
requir
debrid
use
topic
steroid
administr
combin
therapi
may
result
wors
outcom
avoid
howev
scleriti
ensu
may
necessari
use
immunosuppress
reduc
need
enucl
sever
andor
refractori
case
may
result
need
cornea
transplant
phenotyp
seen
pidd
like
candida
patient
defici
seem
highli
suscept
cn
diseas
caus
mmr
vaccin
otherwis
extrem
rare
phenomenon
recent
case
norovir
cn
diseas
describ
associ
novel
yet
unpublish
pidd
suggest
pidd
may
lead
suscept
cn
virus
normal
exhibit
neurotrop
casanova
jl
person
commun
favor
metagenom
approach
studi
cn
sequela
pidd
patient
pidd
cn
also
vulner
viral
induc
immunodysregul
condit
like
primari
hemophagocyt
lymphohistiocytosi
hlh
may
present
isol
cn
diseas
relaps
cn
almost
human
malign
associ
chronic
infect
hbv
hcv
hpv
ebv
htlvi
jcv
merkel
cell
polyomaviru
mcpv
helicobact
pylori
schistosom
liver
fluke
accordingli
pidd
patient
malign
often
associ
chronic
infect
mcpvassoci
merkel
cell
carcinoma
describ
defici
well
form
pidd
larg
followup
cohort
need
refut
confirm
associ
novel
pidd
malign
hyperactiv
ovarian
dysgerminoma
defici
leiomyosarcoma
recent
hymenolepi
nana
found
driven
malign
transform
hiv
patient
like
novel
piddand
pathogenassoci
malign
found
futur
open
inquisit
mind
understand
specif
infect
suscept
pidd
allow
better
understand
host
defens
also
allow
clinician
collabor
microbiolog
laboratori
make
definit
diagnos
provid
best
therapi
review
infect
pidd
within
scope
articl
sever
infect
uniqu
specif
pidd
requir
special
attent
microbiolog
laboratori
three
exampl
provid
g
bethesdensi
gramneg
bacterium
identifi
caus
diseas
patient
cgd
g
bethesdensi
member
methylotroph
group
bacteria
abl
use
singlecarbon
organ
compound
sourc
energi
widespread
environ
rare
human
pathogen
infect
g
bethesdensi
limit
thu
far
patient
cgd
organ
first
detect
adult
patient
indol
recurr
necrot
lymphaden
subsequ
g
bethesdensi
isol
nine
patient
cgd
primarili
caus
lymphaden
two
fatal
treatment
effect
intraven
ceftriaxon
microbiolog
laboratori
alert
concern
g
bethesdensi
infect
allow
proper
cultur
media
charcoal
yeast
extract
cye
agar
lowenstein
jensen
lj
media
appropri
cultur
media
mycoplasma
ureaplasma
spp
molecular
techniqu
becom
wide
use
detect
pathogen
spectrum
infect
previous
detect
serolog
assay
research
laboratori
increas
import
especi
patient
pidd
uniqu
suscept
infect
may
abil
mount
serolog
respons
exampl
infect
group
caus
mycoplasma
ureaplasma
pathogen
known
caus
osteoarticular
infect
antibodi
defici
xla
cvid
recent
mycoplasma
oral
typic
oral
commens
isol
two
patient
defect
activ
delta
syndrom
chronic
lymphaden
one
chronic
splenic
abscess
sm
holland
person
commun
defect
frequent
associ
hypogammaglobulinemia
therefor
would
fit
pattern
mycoplasma
infect
humor
immunodefici
mycoplasma
oral
also
previous
report
caus
bone
diseas
patient
cvid
patient
xla
helicobact
camplyobact
relat
flexispira
bacteria
typic
isol
gi
tract
dissemin
often
lead
chronic
bacteremia
ulcer
bone
infect
xla
patient
higher
suscept
humor
pidd
thought
due
role
igm
play
control
dissemin
pathogen
potenti
iga
provid
mucos
immun
bacteria
fastidi
grow
therefor
suspicion
identif
need
collabor
microbiolog
laboratori
instanc
blood
cultur
media
may
allow
growth
although
longer
incub
period
organ
may
need
molecular
techniqu
identif
sequenc
grow
agar
plate
treatment
often
difficult
requir
combin
antimicrobi
prolong
period
year
relaps
common
review
provid
import
perspect
practic
immunologist
name
part
global
commun
patient
overview
emerg
infect
infecti
concern
travel
serv
foundat
practic
consider
clinician
patient
use
preval
data
estim
number
infect
patient
pidd
tabl
develop
thu
concern
address
review
theoret
impact
consider
number
patient
alreadi
landscap
emerg
infect
natur
highli
dynam
prepar
manuscript
mump
outbreak
usa
occur
new
bunyaviru
outbreak
caus
hlh
pictur
report
sever
fever
thrombocytopenia
syndrom
new
outbreak
hantaviru
seoul
viru
occur
enlarg
demograph
influenza
viru
report
review
list
sever
resourc
mani
updat
real
time
support
effort
provid
inform
patient
doctor
guid
alert
sent
weekli
provid
updat
current
outbreak
around
world
